Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 16/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | RPA1 | P27694 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1110679 | 0.91 | SLC5A1 (0.51) | SLC5A1FAAHMGLL | |
| SCHEMBL3425400 | 0.87 | SLC5A1 (0.46) | SLC5A1RPA1 | |
| SCHEMBL3427610 | 0.87 | RPA1 (0.45) | FAAHMGLLRXFP1RPA1 | |
| SCHEMBL1764962 | 0.87 | FAAH (0.55) | SLC5A1FAAHMGLLRXFP1RPA1 | |
| SCHEMBL3430605 | 0.86 | RXFP1 (0.43) | FAAHRXFP1RPA1 | |
| SCHEMBL3434799 | 0.84 | RPA1 (0.42) | FAAHMGLLRXFP1RPA1 | |
| SCHEMBL3430423 | 0.84 | ALDH1A1 (0.44) | RXFP1RPA1 | |
| SCHEMBL3429460 | 0.81 | RPA1 (0.41) | RXFP1RPA1 | |
| SCHEMBL3427741 | 0.81 | RXFP1 (0.41) | RXFP1RPA1 | |
| SCHEMBL3430811 | 0.80 | RPA1 (0.43) | FAAHMGLLRXFP1RPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254885-A1 | (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES | AiCuris GmbH & Co. KG (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009115213-A1 | (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2009-09-24 | — | — | WO | disclosed |